This study investigated the extent to which occasional cannabis use moderated anxiety and depression outcomes in the Collaborative Care for Anxiety and Panic (CCAP) study, a combined cognitive-behavioral therapy (CBT) and pharmacotherapy randomized effectiveness trial. Participants were 232 adults from six university-based primary care outpatient clinics in three West Coast cities randomized to receive either the CCAP intervention or the usual care condition. Results showed significant (P<.01) evidence of an interaction between treatment group (CCAP vs. usual care) and cannabis use status (monthly vs. less than monthly) for depressive symptoms, but not for panic disorder or social phobia symptoms (all P>.05). Monthly cannabis users' depressive symptoms improved in the CCAP intervention just as much as those who used cannabis less than monthly, whereas monthly users receiving usual care had significantly more depressive symptoms than those using less than monthly. A combined CBT and medication treatment intervention may be a promising approach for the treatment of depression among occasional cannabis users.

Download full-text PDF

Source
http://dx.doi.org/10.1002/da.20248DOI Listing

Publication Analysis

Top Keywords

occasional cannabis
12
anxiety depression
8
randomized effectiveness
8
effectiveness trial
8
ccap intervention
8
usual care
8
depressive symptoms
8
cannabis impact
4
impact anxiety
4
depression treatment
4

Similar Publications

Evaluation of Cannabis Per Se Laws: A Semi-Mechanistic Pharmacometrics Model for Quantitative Characterization of THC and Metabolites in Oral Users.

J Clin Pharmacol

January 2025

Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, USA.

Recreational cannabis use has increased notably in the United States in the past decade, with a recent surge in oral consumption. This trend has raised concerns about driving under the influence. Current cannabis-impaired driving laws lack standardization, with some states implementing blood Δ9-tetrahydrocannabinol (THC) per se limits (1, 2, and 5 ng/mL).

View Article and Find Full Text PDF

As accessibility and legalization of cannabis rise throughout the United States (US), programs have sought guidance about whether its use should be considered a contraindication or, if not a contraindication, what recommendations patients should receive regarding appropriate use before and after metabolic and bariatric surgery (MBS). In this review, medical, nutritional, pharmacological, and psychological considerations are presented by a multidisciplinary group of members of the American Society for Metabolic and Bariatric Surgery (ASMBS). Research suggests several risks associated with long-term cannabis use in the general population, but research in the MBS population, specifically, is limited.

View Article and Find Full Text PDF

Laudable Pus, Cocaine, and the Evolution of Wound Management.

Ophthalmic Plast Reconstr Surg

January 2025

John F. Hardesty, MD, Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri, U.S.A.

Purpose: To review the long history of wound management, including the methods of skin closure, asepsis, and anesthesia. Periocular techniques will be emphasized.

Methods: Literature searches and cross-referencing were used to identify historic reports addressing the management of wounds.

View Article and Find Full Text PDF

Aims: This study aimed to determine the effect of vaporized cannabidiol (CBD) on visual function and vehicle driving performance, given the growing popularity of CBD use worldwide.

Design: Randomized, double-blind, placebo-controlled cross-over experimental study.

Setting: Laboratory of Vision Sciences and Applications, University of Granada, Spain.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!